Wierckx, K., Van Caenegem, E., Schreiner, T., Haraldsen, I., Fisher, A., Toye, K., Kaufman, J., et al. (2014). Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European Network for the Investigation of Gender Incongruence. JOURNAL OF SEXUAL MEDICINE, 11(8), 1999–2011.
Wierckx, Katrien, Eva Van Caenegem, Thomas Schreiner, Ira Haraldsen, Alessandra Fisher, Kaatje Toye, Jean Kaufman, and Guy T’Sjoen. 2014. “Cross-sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-time Follow-up: Results from the European Network for the Investigation of Gender Incongruence.” Journal of Sexual Medicine 11 (8): 1999–2011.
TY - JOUR
UR - http://lib.ugent.be/catalog/pug01:5775928
ID - pug01:5775928
LA - eng
TI - Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European Network for the Investigation of Gender Incongruence
PY - 2014
JO - (2014) JOURNAL OF SEXUAL MEDICINE
SN - 1743-6095
PB - 2014
AU - Wierckx, Katrien 002003257437
AU - Van Caenegem, Eva UZGent 002003300580
AU - Schreiner, Thomas
AU - Haraldsen, Ira
AU - Fisher, Alessandra
AU - Toye, Kaatje GE35 001983133270
AU - Kaufman, Jean
AU - T'Sjoen, Guy GE35 UZGent 001988079866 802000601941 0000-0003-0457-9673
AB - Introduction. Data on the effects of cross-sex hormone therapy (CHT) are limited due to the low prevalence of gender dysphoria, small number of subjects treated at each center, lack of prospective studies, and wide variations in treatment modalities. Aim. The aim of this study is to report the short-term effects of CHT on hormonal and clinical changes, side effects, and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (male-to-female gender dysphoric persons). Methods. This was a multicenter 1-year prospective study in 53 trans men and 53 trans women. Trans men received injections of testosterone undecanoate every 3 months. Trans women younger than 45 years received 50 mg cyproterone acetate (CA) and 4 mg estradiol valerate daily, whereas those older than 45 years received 50 mg CA daily together with 100 mu g/24 hours transdermal 17-beta estradiol. Main Outcome Measures. Sex steroids, prolactin, liver enzymes, lipids, hematocrit, blood pressure, anthropometrics, Ferriman and Gallwey score, and global acne grading scale were measured. Side effects, adverse events, and desired clinical changes were examined. Results. No deaths or severe adverse events were observed. Two trans men developed erythrocytosis, and two had transient elevation of the liver enzymes. Trans men reported an increase in sexual desire, voice instability, and clitoral pain (all P <= 0.01). Testosterone therapy increased acne scores, facial and body hair, and prevalence of androgenetic alopecia. Waist-hip ratio, muscle mass, triglycerides, total cholesterol (C), and LDL-C increased, whereas total body fat mass and HDL-C decreased. Three trans women experienced transient elevation of liver enzymes. A significant increase in breast tenderness, hot flashes, emotionality, and low sex drive was observed (all P = 0.02). Fasting insulin, total body fat mass, and prolactin levels increased, and waist-hip ratio, lean mass, total C, and LDL-C decreased. Conclusions. Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up.
Download RIS file